SARS-CoV-2 Total Assay*: Securing your Community with Science and Scale

Jim Freeman
Vice President, Research and Development, Global Assay Development
Siemens Healthineers | May 11, 2020

The COVID-19 pandemic has profoundly disrupted the world. Tools that can help address the full spectrum of challenges to help secure communities and combat this pandemic are needed. Testing large numbers of individuals for immune response/antibody status against the SARS-CoV-2 virus may help with re-opening society and assessing vaccine response, as well as for managing the potential threat of additional infections.

In this video Jim Freeman discusses how design matters for SARS-CoV-2 antibody assays, especially the smart selection of the S1RBD antigen to detect antibodies that may block the virus entry into cells and how this strategy is aligned with vaccine designs.